NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky is investigating the Board of Directors of Knight Capital Group Inc. (“Knight” or the “Company”) (NYSE: KCG) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Getco Holding Company, LLC (“Getco”).
Click here to learn how to join the action: http://zlk.9nl.com/knight-capital-kcg/, or call: 877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Knight shareholders may elect to receive either $3.75 or one share of common stock in the post-merger company for each share of Knight stock they own. The transaction has total approximate value of $1.4 billion. The investigation concerns whether the Knight Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether Getco is underpaying for Knight shares, thus unlawfully harming Knight stockholders. In particular, Knight stock has a reported Book Value of $6.70 per share for the most recent quarter.
If you own common stock in Knight and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or http://zlk.9nl.com/knight-capital-kcg/.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.